8-K: Evofem Biosciences Secures $1.42 Million in Discounted Convertible Notes and Warrants from Aditxt, Bolstering Liquidity Amidst Stringent Terms

Evofem Biosciences, Inc. has completed a private placement of senior subordinated convertible notes and warrants to Aditxt, Inc., raising approximately $925,000 in net proceeds, subject to terms that include significant investor protections and potential future dilution.

Summary

• Evofem Biosciences, Inc. (the "Company") entered into a Securities Purchase Agreement (SPA) with Aditxt, Inc. on June 26, 2025.
• The Company sold senior subordinated convertible notes (the "Notes") with an aggregate original principal amount of $1,423,076.92.
• Warrants to purchase an aggregate of 92,407,592 shares of common stock (the "Warrants") were also issued.
• Aditxt, Inc. paid approximately $650 for each $1,000 of the principal amount of Notes and Warrants, indicating a significant discount.
• The net proceeds to the Company from this offering were approximately $925,000 after offering costs.
• The Notes accrue interest at a rate of 8% per annum, which increases to 12% upon an Event of Default.
• The Notes are convertible at a conversion price of $0.0154 per share, subject to adjustment.
• The Notes mature on June 26, 2028, with the investor having the right to extend the maturity date under certain conditions, such as an Event of Default or a fundamental transaction.
• The Warrants are exercisable into common stock at an exercise price of $0.0154 per share, allow for cashless exercise, and expire on June 26, 2030 (fifth anniversary of issuance).
• A beneficial ownership limitation prevents the holder (Aditxt) from exceeding 9.99% of the Company's outstanding common stock upon conversion or exercise.
• The Notes contain various covenants, including restrictions on incurring additional indebtedness (except permitted), creating liens (except permitted), making restricted payments, and allowing indebtedness to mature prior to the Notes' maturity date (except Permitted Senior Indebtedness).
• The Company must maintain an independent auditor registered with the Public Company Accounting Oversight Board (PCAOB).
• Events of Default include suspension of common stock trading for five consecutive trading days, failure to cure conversion/delivery failures, insufficient authorized shares, failure to make payments, bankruptcy/insolvency, and default under other indebtedness exceeding $100,000.
• Upon an Event of Default, the holder can require redemption at a premium of 125% of the conversion amount or equity value based on stock price.
• The holder has optional redemption rights related to subsequent placements (25% of gross proceeds) and asset sales (100% of net proceeds), subject to a 'Senior Debt Condition'.
• The Company is restricted from issuing certain equity or equity-linked securities (Variable Rate Transactions) and from effecting stock combinations or reverse stock splits without the consent of 'Required Holders' (Aditxt, Inc.).
• The Company must reserve 150% of the maximum shares issuable upon conversion of Notes and exercise of Warrants.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the extremely dilutive terms of the capital raise, the significant discount at which the notes were sold, and the stringent protective covenants granted to the investor, all of which suggest the Company is in a precarious financial position and had to accept very unfavorable terms to secure funding.

Positives

• The Company successfully secured approximately $925,000 in net proceeds, providing immediate capital for general corporate purposes.
• The transaction is structured as senior subordinated convertible notes, which may offer some flexibility compared to traditional equity raises.
• The beneficial ownership limitation of 9.99% helps prevent immediate, overwhelming control by the investor.

Negatives

• The Notes were sold at a significant discount (approximately $650 for each $1,000 principal amount), indicating a high cost of capital for the Company.
• The conversion and exercise price of $0.0154 per share is very low, suggesting substantial dilution for existing shareholders if the Notes and Warrants are converted/exercised.
• The interest rate on the Notes increases to 12% upon an Event of Default, adding significant financial burden if the Company faces challenges.
• The investor (Aditxt) has strong redemption rights upon a Change of Control (125% premium) or an Event of Default (greater of 125% premium or equity value), which could be costly for the Company.
• The Company is restricted from certain capital-raising activities (Variable Rate Transactions) and stock splits without investor consent, limiting future financial flexibility.
• The requirement to reserve 150% of maximum issuable shares for conversion/exercise indicates a large potential future dilution.

Risks

• Significant dilution risk for existing shareholders due to the low conversion/exercise price of $0.0154 per share for the Notes and Warrants.
• Increased financial burden if the Company defaults, as the interest rate on the Notes jumps to 12% per annum.
• Potential for substantial cash outflows if the investor exercises redemption rights upon a Change of Control or Event of Default, which carry a 125% premium.
• Restrictions on future capital raises (Variable Rate Transactions) and stock splits could hinder the Company's ability to raise funds or manage its capital structure in the future.
• The Company's ability to utilize net operating loss carryforwards (NOLs) for U.S. federal income tax purposes could be adversely affected if the transaction constitutes an ownership change under Section 382 of the Code, though the document states it should not if the investor stays below the Maximum Percentage.
• Risk of delisting or suspension of common stock if the Company fails to comply with Principal Market rules or if trading is suspended for five consecutive trading days.
• Risk of legal proceedings or financial penalties if the Company breaches any covenants or representations in the transaction documents.

Future Outlook

The Company intends to use the net proceeds from this offering for general corporate purposes. The terms of the Notes and Warrants, particularly the low conversion/exercise price and the significant potential for dilution, suggest a focus on immediate liquidity and a willingness to accept unfavorable terms to secure funding. The restrictions on future capital raises and stock splits indicate a constrained financial environment for the Company.

Management Comments

• The Company acknowledges and agrees that each Buyer is acting solely in the capacity of an arms length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby.
• The Company acknowledges that its obligation to issue the Conversion Shares and Warrant Shares is absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other stockholders.
• The Company and its board of directors have taken all necessary action to render inapplicable any control share acquisition, interested stockholder, business combination, poison pill, stockholder rights plan or other similar anti-takeover provision.

Industry Context

This capital raise by Evofem Biosciences, a company in the biotechnology/pharmaceutical sector, highlights the challenges smaller, development-stage companies often face in securing financing. The highly dilutive nature of the terms, including discounted convertible notes and warrants with a very low conversion price, is indicative of a company in a distressed or high-risk funding environment, where traditional equity or debt financing may be difficult to obtain on more favorable terms. The investor's strong protective provisions, such as redemption rights and restrictions on future corporate actions, are common in such high-risk investments.

Comparison to Industry Standards

• The discount on the notes (paying $650 for $1,000 principal) and the very low conversion/exercise price ($0.0154) are significantly worse than typical financing terms for healthy, growing companies in the biotech sector, which usually secure funding at or closer to market prices with less immediate dilution.
• The 8% standard interest rate and 12% default interest rate on the notes are relatively high, reflecting the perceived risk of the Company compared to more established pharmaceutical or biotech firms that can access capital at lower rates.
• The 125% redemption premium upon an Event of Default or Change of Control is a strong protective measure for the investor, exceeding standard premiums in less risky financing arrangements.
• The beneficial ownership blocker at 9.99% is a common feature to avoid triggering certain regulatory or exchange reporting requirements for the investor, but the overall structure still allows for significant potential ownership by the investor.
• The restrictions on future 'Variable Rate Transactions' and stock splits without investor consent are more stringent than typical financing agreements, indicating a significant concession by Evofem Biosciences to secure this funding.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Significant potential for dilution due to the low conversion/exercise price of the Notes and Warrants. Existing equity value is likely to be negatively impacted.
• **Creditors:** The new Notes are senior subordinated, meaning they rank below Permitted Senior Indebtedness but senior to other general unsecured indebtedness, potentially impacting the recovery prospects of other unsecured creditors.
• **Management:** The terms of the financing, including restrictions on future capital raises and stock splits, may limit management's strategic and financial flexibility.

Next Steps

• The Company will use the proceeds for general corporate purposes.
• The Company must file a Current Report on Form 8-K describing the material terms of the transactions and attaching the relevant documents.
• The Company must timely file all reports required by the SEC under the 1934 Act.
• The Company must secure and maintain the listing or designation for quotation of all issuable shares on the Principal Market.
• The Company must at all times reserve 150% of the maximum shares issuable upon conversion of Notes and exercise of Warrants, taking corporate action to increase authorized shares if necessary.

Key Dates

Recommendation

Keywords

Convertible Notes, Warrants, Private Placement, Capital Raise, Dilution, SEC Filing, 8-K, Evofem Biosciences, Aditxt, Debt Financing, Equity Financing, Corporate Governance, Risk Factors